International Stem Cell Corporation (ISCO) Uses Mu
Post# of 124
Posted On: 11/30/2015 6:07:44 PM
International Stem Cell Corporation (ISCO) Uses Multiple Business Units to Generate Even More Revenue
International Stem Cell Corporation (OTC: ISCO) focuses on utilizing patented human parthenogenetic stem cells (hPSC), developed from unfertilized embryos, to treat Parkinson’s, retinal, and liver diseases where replacing dead and dying cells with new ones seems most effective. However, the road to commercialization and FDA approval is a long one. Therefore, the company has two wholly-owned subsidiaries that generate money in the meantime: Lifeline Skin Care, Inc. and Lifeline Cell Technology, LLC.
The first, Lifeline Skin Care, Inc., develops, produces, and markets a line of anti-aging cosmetic skin care products. These products use the company’s scientific rejuvenation breakthrough of non-embryonic stem cells to improve the look and feel of skin. These products include neck and eye firming creams, moisturizers, cleansers, and more. Sold all over the world, this cosmetic line promises youthful and healthy looking skin.
The second, Lifeline Cell Technology, LLC, develops, manufactures, and sells human cell culture products along with optimized reagents for laboratory research purposes. For example, the company offers VascuLife®SMC, a human smooth muscle cell medium optimized for the culture of human smooth muscle cells. This provides 15 population doublings at high growth rates. The company also sells Normal Human Mammary Epithelial Cells (HMEC) that provide a serum-free culture model for research on breast cancer, carcinogen screening, and other areas of breast research. All of Lifeline Cell Technology products are rigorously tested to the highest degree for maximum laboratory research operations.
In a news release, Andrey Semechkin, Ph.D., CEO, and co-chairman of ISCO recently stated, “We are maintaining our position as a leader in the regenerative medicine field and the overall operating income of our biomedical businesses continues to grow.” The company continues to manufacture and market its proprietary innovations while advancing developments in treatments of various diseases using stem cells.
To find out what the buzz is all about, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
International Stem Cell Corporation (OTC: ISCO) focuses on utilizing patented human parthenogenetic stem cells (hPSC), developed from unfertilized embryos, to treat Parkinson’s, retinal, and liver diseases where replacing dead and dying cells with new ones seems most effective. However, the road to commercialization and FDA approval is a long one. Therefore, the company has two wholly-owned subsidiaries that generate money in the meantime: Lifeline Skin Care, Inc. and Lifeline Cell Technology, LLC.
The first, Lifeline Skin Care, Inc., develops, produces, and markets a line of anti-aging cosmetic skin care products. These products use the company’s scientific rejuvenation breakthrough of non-embryonic stem cells to improve the look and feel of skin. These products include neck and eye firming creams, moisturizers, cleansers, and more. Sold all over the world, this cosmetic line promises youthful and healthy looking skin.
The second, Lifeline Cell Technology, LLC, develops, manufactures, and sells human cell culture products along with optimized reagents for laboratory research purposes. For example, the company offers VascuLife®SMC, a human smooth muscle cell medium optimized for the culture of human smooth muscle cells. This provides 15 population doublings at high growth rates. The company also sells Normal Human Mammary Epithelial Cells (HMEC) that provide a serum-free culture model for research on breast cancer, carcinogen screening, and other areas of breast research. All of Lifeline Cell Technology products are rigorously tested to the highest degree for maximum laboratory research operations.
In a news release, Andrey Semechkin, Ph.D., CEO, and co-chairman of ISCO recently stated, “We are maintaining our position as a leader in the regenerative medicine field and the overall operating income of our biomedical businesses continues to grow.” The company continues to manufacture and market its proprietary innovations while advancing developments in treatments of various diseases using stem cells.
To find out what the buzz is all about, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)